Literature DB >> 1733939

Search for the heparin antithrombin III-binding site precursor.

R J Linhardt1, H M Wang, D Loganathan, J H Bae.   

Abstract

The last step of heparin biosynthesis is thought to involve the action of 3-O-sulfotransferase resulting in the formation of an antithrombin III (ATIII) binding site required for heparin's anticoagulant activity. The isolation of a significant fraction of heparin chains without antithrombin III-binding sites and having low affinity for ATIII suggests the presence of a precursor site, lacking the 3-O-sulfate group. Porcine mucosal heparin was depolymerized into a mixture of oligosaccharides using heparin lyase. One of these oligosaccharides was derived from heparin's ATIII-binding site. In an effort to find the ATIII-binding site precursor, the structures of several minor oligosaccharides were determined. A greater than 90% recovery of oligosaccharides (on a mole and weight basis) was obtained for both unfractionated and affinity-fractionated heparins. An oligosaccharide arising from the ATIII-binding site precursor was found that comprised only 0.8 mol % of the oligosaccharide product mixture. This oligosaccharide was only slightly enriched in heparin having a low affinity for ATIII and only slightly disenriched in high affinity heparin. The small number of these ATIII-binding site precursors, found in unfractionated and fractionated heparins, suggests the existence of a low ATIII affinity heparin may not simply be the result of the incomplete action of 3-O-sulfotransferase in the final step in heparin biosynthesis. Rather these data suggest that some earlier step, involved in the formation of placement of these precursor sites, may be primarily responsible for high and low ATIII affinity heparins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1733939

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Heparinase 1 selectivity for the 3,6-di-O-sulfo-2-deoxy-2-sulfamido-alpha-D-glucopyranose (1,4) 2-O-sulfo-alpha-L-idopyranosyluronic acid (GlcNS3S6S-IdoA2S) linkages.

Authors:  Zhongping Xiao; Wenjing Zhao; Bo Yang; Zhenqing Zhang; Huashi Guan; Robert J Linhardt
Journal:  Glycobiology       Date:  2010-08-20       Impact factor: 4.313

2.  Structural Analysis of Heparin-Derived 3-O-Sulfated Tetrasaccharides: Antithrombin Binding Site Variants.

Authors:  Yin Chen; Lei Lin; Isaac Agyekum; Xing Zhang; Kalib St Ange; Yanlei Yu; Fuming Zhang; Jian Liu; I Jonathan Amster; Robert J Linhardt
Journal:  J Pharm Sci       Date:  2016-12-20       Impact factor: 3.534

3.  Interaction of heparin with synthetic antithrombin III peptide analogues.

Authors:  J Bae; U R Desai; A Pervin; E E Caldwell; J M Weiler; R J Linhardt
Journal:  Biochem J       Date:  1994-07-01       Impact factor: 3.857

4.  Chondroitin sulphate composition and structure in alternatively spliced CD44 fusion proteins.

Authors:  M Piepkorn; P Hovingh; K L Bennett; A Aruffo; A Linker
Journal:  Biochem J       Date:  1997-10-15       Impact factor: 3.857

5.  Toward an artificial Golgi: redesigning the biological activities of heparan sulfate on a digital microfluidic chip.

Authors:  Jeffrey G Martin; Megha Gupta; Yongmei Xu; Srinivas Akella; Jian Liu; Jonathan S Dordick; Robert J Linhardt
Journal:  J Am Chem Soc       Date:  2009-08-12       Impact factor: 15.419

6.  Structure of heparin fragments with high affinity for lipoprotein lipase and inhibition of lipoprotein lipase binding to alpha 2-macroglobulin-receptor/low-density-lipoprotein-receptor-related protein by heparin fragments.

Authors:  A Larnkjaer; A Nykjaer; G Olivecrona; H Thøgersen; P B Ostergaard
Journal:  Biochem J       Date:  1995-04-01       Impact factor: 3.857

7.  Assays for determining heparan sulfate and heparin O-sulfotransferase activity and specificity.

Authors:  Eric Sterner; Lingyun Li; Priscilla Paul; Julie M Beaudet; Jian Liu; Robert J Linhardt; Jonathan S Dordick
Journal:  Anal Bioanal Chem       Date:  2013-11-23       Impact factor: 4.142

Review 8.  Engineered heparins as new anticoagulant drugs.

Authors:  Deepika Vaidyanathan; Asher Williams; Jonathan S Dordick; Mattheos A G Koffas; Robert J Linhardt
Journal:  Bioeng Transl Med       Date:  2016-11-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.